Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: Improvement in the sensitivity or specificity?

Journal of International Medical Research

Volumn 41, Issue 4, 2013, Pages 975-983

  Wu, Gang ^a   Wang, Jie ^a   Zhou, Zhongwen ^a   Li, Tianyi ^a   Tang, Feng ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

cytokeratin 19; galectin 3; human bone marrow endothelial cell 1; Papillary thyroid carcinoma; tyrosine kinase type cell surface receptor HER2

Indexed keywords

CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALECTIN 3; HUMAN BONE MARROW ENDOTHELIAL CELL 1; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEQUENCE HOMOLOGY; SEX DIFFERENCE; THYROID CARCINOMA;

EID: 84887399103     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513490617     Document Type: Article

References (41)

1. Davies L,Welch HG.Increasing incidence of thyroid cancer in the United States, 1973-2002.JAMA. 2006;295:2164-2167.
2. Londero SC,Krogdahl A,Bastholt L,et al.Papillary thyroid carcinoma in Denmark 1996-2008: An investigation of changes in incidence.Cancer Epidemiol. 2013;37:e1-e6.
3. Baloch ZW,LiVolsi VA.Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow.Expert Rev Mol Diagn. 2005;5:573-584.
4. Papale F,Cafiero G,Grimaldi A,et al.Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: validation of molecular markers and technology innovation.J Cell Physiol. 2013;228:968-974.
5. Weber T,Schilling T,Büchler MW.Thyroid carcinoma.Curr Opin Oncol. 2006;18:30-35.
6. Saleh HA,Feng J,Tabassum F,et al.Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy.Cytojournal. 2009;6:18-18.
7. Krzeslak A,Gaj Z,Pomorski L,et al.Expression of cytokeratin 19 in the cytosolic fraction of thyroid lesions: ELISA and Western blot analysis.Mol Med Rep. 2008;1:565-569.
8. Ozolins A,Narbuts Z,Strumfa I,et al.Diagnostic utility of immunohistochemical panel in various thyroid pathologies.Langenbecks Arch Surg. 2010;395:885-891.
9. Nga ME,Lim GS,Soh CH,et al.HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.Diagn Cytopathol. 2008;36:550-556.
10. Schmitt AC,Cohen C,Siddiqui MT.Paired box gene 8, HBME-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma diagnostic utility.Cancer Cytopathol. 2010;118:196-202.
11. Saleh HA,Jin B,Barnwell J,et al.Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.Diag Pathol. 2010;5:9-9.
12. Verkooijen HM,Fioretta G,Pache JC,et al.Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland.Cancer Causes Control. 2003;14:13-17.
13. Tian X,Cong M,Zhou W,et al.Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer.J Int Med Res. 2008;36:699-703.
14. Petterino C,Rossetti E,Bertoncello D,et al.Immunohistochemical detection of P-glycoprotein (clone C494) in canine mammary gland tumours.J Vet Med A Physiol Pathol Clin Med. 2006;53:174-178.
15. Hong SC,Song JY,Lee JK,et al.Significance of CD44v6 expression in gynecologic malignancies.J Obstet Gynaecol Res. 2006;32:379-386.
16. Cho Mar K,Eimoto T,Tateyama H,et al.Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions.Histopathology. 2006;48:286-294.
17. Beesley MF,McLaren KM.Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules.Histopathology. 2002;41:236-243.
18. LiVolsi VA.Papillary thyroid carcinoma: an update.Modern Pathol. 2011;24:S1-S9.
19. Grodski S,Delbridge L.An update on papillary microcarcinoma.Curr Opin Oncol. 2009;21:1-4.
20. Xing CY,Dong LW,Wang XH,et al.Retrospective analysis of diagnosis by intraoperative frozen section and routine paraffin embedded tissue in 638 thyroid disease patients.Clin Oncol Cancer Res. 2009;6:359-361.
21. Erkiliç S,Koçer NE.The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease.Endocr Pathol. 2005;16:63-66.
22. Erkiliç S,Aydin A,Koçer NE.Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid.Endocr Pathol. 2002;13:207-211.
23. El Demellawy D,Nasr A,Alowami S.Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid.Diagn Pathol. 2008;3:5-5.
24. Zhu X,Sun T,Lu H,et al.Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.J Clin Pathol. 2010;63:786-789.
25. Zosin I,Comianu M,Golu I,et al.Usefulness of immunohistochemistry in the diagnosis of nodular thyroid disease.Acta Endocrinol (Buc). 2007;3:437-449.
26. Takenaka Y,Fukumori T,Raz A.Galectin-3 and metastasis.Glycoconj J. 2004;19:543-549.
27. Cui W,Sang W,Zheng S,et al.Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.Clin Lab. 2012;58:673-680.
28. Danguy A,Camby I,Kiss R.Galectins and cancer.Biochim Biophys Acta. 2002;1572:285-293.
29. Samija I,Mateša N,Lukač J,et al.Galectin-3 and CD44v6 as markers for preoperative diagnosis of thyroid cancer by RT-PCR.Diag Mol Pathol. 2011;20:233-241.
30. Asa SL.The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.Endocr Pathol. 2005;16:295-309.
31. Bateman AC,al-Talib RK,Newman T,et al.Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.Histopathology. 1997;30:49-56.
32. González-Lois C,Ballestin C,Sotelo MT,et al.Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.Histopathology. 2001;38:528-534.
33. Saggiorato E,De Pompa R,Volante M,et al.Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.Endocr Relat Cancer. 2005;12:305-317.
34. Paunovic I,Isic T,Havelka M,et al.Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.APMIS. 2012;120:368-379.
35. Casey MB,Lohse CM,Lloyd RV.Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.Endocr Pathol. 2003;14:55-60.
36. Schechter AL,Stern DF,Vaidyanathan L,et al.The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.Nature. 1984;312:513-516.
37. Hussein MR,Abd-Elwahed SR,Abdulwahed AR.Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.Cell Biol Int. 2008;32:698-707.
38. Bargmann CI,Hung MC,Weinberg RA.The neu oncogene encodes an epidermal growth factor receptor-related protein.Nature. 1986;319:226-230.
39. Schlüter B,Gerhards R,Strumberg D,et al.Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.J Cancer Res Clin Oncol. 2010;136:1389-1400.
40. Eltze E,Wülfing C,Von Struensee D,et al.Cox-2 and Her2/neu co-expression in invasive bladder cancer.Int J Oncol. 2005;26:1525-1531.
41. Seçkin S,Karagece Ü.Expression of CK-19, cErbB2, galectin-3, and p53 in papillary thyroid carcinomas.Turk J Med Sci. 2010;40:207-212.